A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

Inclusion Criteria: * Is male or female, 18 to 60 years of age. * Has a history of chronic migraine as classified by the International Headache Classification, ICHD-2R (i.e. must demonstrate an average of \>=15 headache days per month, of which \>=8 must be migraine days or \>=8 days of migraine-specific acute medication-ergotamine or triptans for at least 3 months prior to study. * Must demonstrate at least \>=8 migraine days or \>=8 days of migraine specific acute medications- ergotamine or triptans during 30 day baseline screening. * Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache). * Will have a previous history of failing at least one prophylactic treatment, which can include anti-seizure medications and/or TCA's prescribed for the treatment of chronic migraine. * Must be considered a non-responder to previous treatment with Botox. Botox failure will be defined by previous documentation (at the discretion of the PI) or as having less than 30% reduction of headache days per month on Botox. * Will have not had botulinum toxin with in 4 months before study enrollment. * If female of childbearing potential, will have a negative urine pregnancy test at Visits 1 and 7, and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as determined by the investigator. 1. Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug (a minimum of 7 days); or, 2. Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or, 3. Sterilization of male partner; or, 4. Intrauterine device with published data showing lowest expected failure rate is less than 1% per year; or, 5. Double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or, 6. Hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study. Protocol Number/v.1/06 Jun 2012 7 * Must be in generally good health as confirmed by medical history, baseline physical exam, baseline neurological exam and vital signs. Exclusion Criteria: * Is unable to understand the study requirements, the informed consent, or complete headache records as required per protocol. * Is pregnant, actively trying to become pregnant, or breast-feeding. * Has a significant systemic disease that is equally painful or more painful than migraine. * Has a progressive neurological disorder such as MS. * Has a history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome such as HIV. * Has sensitivity to proteins of porcine origin. * Has a known or 'new' diagnosis of diabetes mellitus (if screening blood glucose is suspicious for diabetes \[\> or equal to 126 mg/dL or \> or equal to 7 mmol/L if fasting;\> or equal to 200 mg/dL or 11.1 mmol/L if random testing\] a patient should be further evaluated for diabetes mellitus), or a known or 'new' diagnosis of hypothyroidism not adequately controlled with medication. * Has previously taken Acthar for any reason. * Has any contraindications listed on the Acthar PI. * Has a history of cluster headache, chronic tension type headache, or headache due to medication over use according to IHS guidelines, in the 3 months prior to study enrollment or during the baseline phase. * Has received any other investigative drug 30 days prior to enrollment in this study. * Who in the opinion of the Principal Investigator has a condition for which they should not be enrolled in the study.